Vorasidenib- A Paradigm Shift in IDH1- or IDH2-Mutant Low-Grade Glioma Treatment

J Pak Med Assoc. 2024 Oct;74(10):1912-1913. doi: 10.47391/JPMA.20428.
No abstract available

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Brain Neoplasms* / drug therapy
  • Brain Neoplasms* / genetics
  • Glioma* / drug therapy
  • Glioma* / genetics
  • Humans
  • Isocitrate Dehydrogenase* / genetics
  • Mutation
  • Pyridines / therapeutic use
  • Triazines / therapeutic use

Substances

  • Isocitrate Dehydrogenase
  • IDH1 protein, human
  • IDH2 protein, human
  • Antineoplastic Agents
  • Pyridines
  • Triazines